Corient Private Wealth LP Invests $50.01 Million in CVS Health Corporation $CVS

Corient Private Wealth LP purchased a new stake in CVS Health Corporation (NYSE:CVS) in the 2nd quarter, Holdings Channel reports. The firm purchased 644,830 shares of the pharmacy operator’s stock, valued at approximately $50,011,000.

Several other hedge funds have also added to or reduced their stakes in CVS. Handelsbanken Fonder AB boosted its holdings in shares of CVS Health by 83.6% in the second quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock valued at $112,729,000 after buying an additional 496,124 shares during the period. State Street Corp raised its holdings in shares of CVS Health by 2.1% during the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after acquiring an additional 1,245,457 shares during the period. Legal & General Group Plc lifted its position in CVS Health by 0.3% in the 4th quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock valued at $738,777,000 after acquiring an additional 31,249 shares in the last quarter. Deutsche Bank AG boosted its stake in CVS Health by 28.4% in the 4th quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock worth $370,333,000 after purchasing an additional 1,031,998 shares during the period. Finally, Oppenheimer Asset Management Inc. bought a new position in CVS Health during the 2nd quarter worth about $49,622,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of NYSE CVS opened at $92.88 on Friday. The stock has a market capitalization of $118.79 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 0.86 and a beta of 0.61. The business has a 50-day moving average of $101.52 and a 200-day moving average of $89.43. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter in the prior year, the company posted $1.81 earnings per share. CVS Health’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. CVS Health’s dividend payout ratio is currently 70.37%.

Analyst Ratings Changes

A number of brokerages have recently commented on CVS. UBS Group boosted their price target on CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Morgan Stanley increased their price objective on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Weiss Ratings upgraded CVS Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Truist Financial upped their price target on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Finally, Bank of America raised their price target on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Twenty-two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.17.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.